Please login to the form below

Not currently logged in
Email:
Password:

GSK appoints Dr Richard Jones to Rare Disease Unit

He joins the pharma company from Genzyme

Richard Jones - GSK, global commercial leader, rare disease unitGlaxoSmithKline (GSK) has appointed Dr Richard Jones to its Rare Disease Unit in a role that will see him guide commercial strategy across CNS, neuomuscular disorders, rare malignancies and haematology franchises.

He joins the pharma company as global commercial leader (CNS, muscular disorders, rare malignancies and haematology) from Genzyme, where he served as director, EMEA oncology and transplant.

In this position Dr Jones was commercially responsible for the portfolio of assets as well as managing the integration and transition of business development projects.

Prior to Genzyme, he served at Shire in various international commercial and therapy area project lead roles and then worked at the MSI consultancy.

GSK's Rare Disease Unit was set up in February 2010 to leverage its existing capabilities and partnerships and establish further in-licensing opportunities.

In April of that year the pharma company signed a deal $1.5bn potentially worth with Isis Pharmaceuticals to develop new drugs for rare and serious diseases using Isis' antisense drug discovery platform.

Meanwhile, in August 2011 GSK signed a deal with Italian biotech company MolMed to develop a production process for an ex vivo gene therapy for Adenosine Deaminase Deficiency - Severe Combined Immune Deficiency (ADA-SCID), commonly referred to as 'bubble boy disease'.

16th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics